藍帆醫療(002382.SZ)：北京信聿的持股比例減少到佔現總股本的9.8%
格隆匯1月10日丨藍帆醫療(002382.SZ)公佈，2021年9月4日，公司披露了《關於持股5%以上股東未來減持計劃預披露的公吿》(公吿編號：2021-084)，公司持股5%以上股東北京信聿投資中心(有限合夥)(“北京信聿”)擬通過大宗交易方式持其持有的公司股份合計不超過公司總股本的4%，擬通過集中競價方式減持其持有的公司股份合計不超過公司總股本的2%，合計不超過公司總股本的6%。截至2022年1月7日，北京信聿本次減持期間通過集中競價、大宗交易方式累計減持公司股份1486.2549萬股；
2021年3月16日，公司披露了《關於持股5%以上股東減持計劃期限屆滿暨未來減持計劃預披露的公吿》(公吿編號：2021-012)，2021年7月10日，公司在公司指定的信息披露媒體上披露了《關於持股5%以上股東減持計劃期限屆滿的公吿》(公吿編號：2021-069)，北京信聿在此次減持期間通過集中競價和大宗交易的方式合計減持公司股份1667.8825萬股；
公司於2021年6月8日召開2020年年度股東大會，審議通過了《關於重大資產重組標業績補償方案的議案》，同意公司以1元總價回購註銷業績承諾方北京信聿持有的公司2478.7109萬股股份。2021年6月23日，本次回購註銷已完成，北京信聿持有的公司股份減少2478.7109萬股(股份性質為限售股)；
受公司公開發行可轉換公司債券持有人陸續轉股影響，公司總股本不斷增加，北京信聿持股比例持續被稀釋；
截至2022年1月7日，綜合上述原因，北京信聿持有股份合計減少5632.8483萬股，持股比例由佔原總股本的14.80%減少到佔現總股本的9.80%，變動比例達到5%；
上述權益變動不觸及要約收購，不會導致公司控股股東及實際控制人發生變化，不涉及公司控制權變更。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
